Review



mouse cd74 apc-conjugated antibody  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bio-Techne corporation mouse cd74 apc-conjugated antibody
    Mouse Cd74 Apc Conjugated Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cd74+apc-conjugated+antibody/Mouse+CD74+APC-conjugated+Antibody/bio-techne+corporation___fab7478a
    Average 94 stars, based on 7 article reviews
    mouse cd74 apc-conjugated antibody - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Neutralization:

    Article Title: Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
    Article Snippet: buffer and then incubated with 5 μg/ml Alexa 647 labeled donkey anti-human Fc antibody (Jackson ImmunoResearch) on ice for another 60 minutes. For the anti-mouse CD74 antibody conjugated to APC from R&D system (Cat. No. FAB7478A) which has no concentration information available, the antibody was mixed with cells at 1:1 volume ratio and then started 1:4 serial dilution. Unstained cells and cells st

    Flow Cytometry:

    Article Title: Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
    Article Snippet: buffer and then incubated with 5 μg/ml Alexa 647 labeled donkey anti-human Fc antibody (Jackson ImmunoResearch) on ice for another 60 minutes. For the anti-mouse CD74 antibody conjugated to APC from R&D system (Cat. No. FAB7478A) which has no concentration information available, the antibody was mixed with cells at 1:1 volume ratio and then started 1:4 serial dilution. Unstained cells and cells st



    Similar Products

    mouse cd74 apc-conjugated antibody  (Bio-Techne corporation)
    94
    Bio-Techne corporation mouse cd74 apc-conjugated antibody
    Mouse Cd74 Apc Conjugated Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cd74+apc-conjugated+antibody/Mouse+CD74+APC-conjugated+Antibody/bio-techne+corporation___fab7478a
    Average 94 stars, based on 1 article reviews
    mouse cd74 apc-conjugated antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti mouse cd74  (R&D Systems)
    94
    R&D Systems anti mouse cd74
    Fig. 5. IRF8 control of components of the MHCII complex. (A) FACS analysis of H2-IA/IE (left) and HLA-DR (right) in models of IRF8 KO; WB of IRF8 in RIVA and SU-DHL2 KO models, and WB of MHCII in all IRF8 KO models in DLBCL. (B) FACS of <t>CD74</t> in models of IRF8 KO. (C) FACS of H2-DM and HLA-DM in IRF8 KO models. (D) Left: FACS of CD74 and H2-DM in the IRF8 KO A20 lymphoma model “rescued” with IRF8 WT or missense or nonsense mutants (top and bottom). Right: FACS of CD74 and H2-DM in the IRF8 KO 2PK-3 lymphoma model “rescued” with IRF8 WT or missense and nonsense mutants (top and bottom). (E) Top: ChIP-qPCR of IRF8 binding to the indicated promot- ers – controls are IgG pull down, and a genomic region without a predicted IRF8 binding site (neg ctrl). Bottom: ChIP-qPCR of IRF8 WT, N87Y, or I424T binding to the Cd74, H2-Dm, Ciita, or H2-Aa promoters. (F) Top: WB of CD74 in 2PK-3 and A20 CD74-KO models. Bottom: IL-2 levels and % of CD4/CD25+ cells in IRF8/CD74 WT, IRF8 KO, or CD74 KOs models. (G) Left to right: A20, 2PK-3, and BCL1 models of IRF8 KO with CD74 ectopic expression (ee). WB of CD74-FLAG, IL-2 levels and % of CD4/CD25+ cells in IRF8/ CD74 WT, IRF8 KO, or IRF8KO + CD74. (H) Left: WB of CD74-FLAG in IRF8 WT, N87Y, and I424T A20 models. Right: IL-2 levels and % of CD4/CD25+ cells in IRF8 WT, N87Y, and I424T (−/+ CD74 ectopic expression) models. Data are means ± SD of three biological replicates. FACS displayed as relative mean fluorescence intensity (MFI). P values are from ANOVA, with Bonferroni or Fisher’s LSD posttest, or two-sided Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
    Anti Mouse Cd74, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cd74+apc-conjugated+antibody/Mouse+CD74+APC-conjugated+Antibody/pm38996030-360-168-172
    Average 94 stars, based on 1 article reviews
    anti mouse cd74 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti mouse cd74 antibody conjugated to apc  (R&D Systems)
    94
    R&D Systems anti mouse cd74 antibody conjugated to apc
    Figure 1: SP7219 and STRO-001 showed similar high affinity binding to human and cynomolgus monkey <t>CD74,</t> no binding to mouse CD74. Anti-GFP antibody SP7824 was used as negative control in the cell binding experiments. (A) SP7219 and STRO-001 showed similar high affinity cell binding on CHO cells over-expressing human and cynomolgus monkey CD74. (B) SP7219 and STRO-001 showed no binding to mouse B cell line A20. The mouse CD74 expression on A20 was confirmed by a commercial anti- mouse-CD74 antibody from R&D Systems.
    Anti Mouse Cd74 Antibody Conjugated To Apc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cd74+apc-conjugated+antibody/Mouse+CD74+APC-conjugated+Antibody/pm36634212-134-2-9
    Average 94 stars, based on 1 article reviews
    anti mouse cd74 antibody conjugated to apc - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    cat no fab7478a  (R&D Systems)
    94
    R&D Systems cat no fab7478a
    Figure 1: SP7219 and STRO-001 showed similar high affinity binding to human and cynomolgus monkey <t>CD74,</t> no binding to mouse CD74. Anti-GFP antibody SP7824 was used as negative control in the cell binding experiments. (A) SP7219 and STRO-001 showed similar high affinity cell binding on CHO cells over-expressing human and cynomolgus monkey CD74. (B) SP7219 and STRO-001 showed no binding to mouse B cell line A20. The mouse CD74 expression on A20 was confirmed by a commercial anti- mouse-CD74 antibody from R&D Systems.
    Cat No Fab7478a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cd74+apc-conjugated+antibody/Mouse+CD74+APC-conjugated+Antibody/pmc09836384-140-11-9
    Average 94 stars, based on 1 article reviews
    cat no fab7478a - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti cd74  (R&D Systems)
    94
    R&D Systems anti cd74
    Figure 1: SP7219 and STRO-001 showed similar high affinity binding to human and cynomolgus monkey <t>CD74,</t> no binding to mouse CD74. Anti-GFP antibody SP7824 was used as negative control in the cell binding experiments. (A) SP7219 and STRO-001 showed similar high affinity cell binding on CHO cells over-expressing human and cynomolgus monkey CD74. (B) SP7219 and STRO-001 showed no binding to mouse B cell line A20. The mouse CD74 expression on A20 was confirmed by a commercial anti- mouse-CD74 antibody from R&D Systems.
    Anti Cd74, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cd74+apc-conjugated+antibody/Mouse+CD74+APC-conjugated+Antibody/pmc07963458-268-0-6
    Average 94 stars, based on 1 article reviews
    anti cd74 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti mhc ii molecule rat antibody  (R&D Systems)
    94
    R&D Systems anti mhc ii molecule rat antibody
    Figure 1: SP7219 and STRO-001 showed similar high affinity binding to human and cynomolgus monkey <t>CD74,</t> no binding to mouse CD74. Anti-GFP antibody SP7824 was used as negative control in the cell binding experiments. (A) SP7219 and STRO-001 showed similar high affinity cell binding on CHO cells over-expressing human and cynomolgus monkey CD74. (B) SP7219 and STRO-001 showed no binding to mouse B cell line A20. The mouse CD74 expression on A20 was confirmed by a commercial anti- mouse-CD74 antibody from R&D Systems.
    Anti Mhc Ii Molecule Rat Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cd74+apc-conjugated+antibody/Mouse+CD74+APC-conjugated+Antibody/pm32278814-69-32-37
    Average 94 stars, based on 1 article reviews
    anti mhc ii molecule rat antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    r d systems fab7478a mouse  (R&D Systems)
    94
    R&D Systems r d systems fab7478a mouse
    Figure 1: SP7219 and STRO-001 showed similar high affinity binding to human and cynomolgus monkey <t>CD74,</t> no binding to mouse CD74. Anti-GFP antibody SP7824 was used as negative control in the cell binding experiments. (A) SP7219 and STRO-001 showed similar high affinity cell binding on CHO cells over-expressing human and cynomolgus monkey CD74. (B) SP7219 and STRO-001 showed no binding to mouse B cell line A20. The mouse CD74 expression on A20 was confirmed by a commercial anti- mouse-CD74 antibody from R&D Systems.
    R D Systems Fab7478a Mouse, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cd74+apc-conjugated+antibody/Mouse+CD74+APC-conjugated+Antibody/pmc07145990__Data_Sheet_1-2-53-53
    Average 94 stars, based on 1 article reviews
    r d systems fab7478a mouse - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 5. IRF8 control of components of the MHCII complex. (A) FACS analysis of H2-IA/IE (left) and HLA-DR (right) in models of IRF8 KO; WB of IRF8 in RIVA and SU-DHL2 KO models, and WB of MHCII in all IRF8 KO models in DLBCL. (B) FACS of CD74 in models of IRF8 KO. (C) FACS of H2-DM and HLA-DM in IRF8 KO models. (D) Left: FACS of CD74 and H2-DM in the IRF8 KO A20 lymphoma model “rescued” with IRF8 WT or missense or nonsense mutants (top and bottom). Right: FACS of CD74 and H2-DM in the IRF8 KO 2PK-3 lymphoma model “rescued” with IRF8 WT or missense and nonsense mutants (top and bottom). (E) Top: ChIP-qPCR of IRF8 binding to the indicated promot- ers – controls are IgG pull down, and a genomic region without a predicted IRF8 binding site (neg ctrl). Bottom: ChIP-qPCR of IRF8 WT, N87Y, or I424T binding to the Cd74, H2-Dm, Ciita, or H2-Aa promoters. (F) Top: WB of CD74 in 2PK-3 and A20 CD74-KO models. Bottom: IL-2 levels and % of CD4/CD25+ cells in IRF8/CD74 WT, IRF8 KO, or CD74 KOs models. (G) Left to right: A20, 2PK-3, and BCL1 models of IRF8 KO with CD74 ectopic expression (ee). WB of CD74-FLAG, IL-2 levels and % of CD4/CD25+ cells in IRF8/ CD74 WT, IRF8 KO, or IRF8KO + CD74. (H) Left: WB of CD74-FLAG in IRF8 WT, N87Y, and I424T A20 models. Right: IL-2 levels and % of CD4/CD25+ cells in IRF8 WT, N87Y, and I424T (−/+ CD74 ectopic expression) models. Data are means ± SD of three biological replicates. FACS displayed as relative mean fluorescence intensity (MFI). P values are from ANOVA, with Bonferroni or Fisher’s LSD posttest, or two-sided Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Journal: Science advances

    Article Title: IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes.

    doi: 10.1126/sciadv.adk2091

    Figure Lengend Snippet: Fig. 5. IRF8 control of components of the MHCII complex. (A) FACS analysis of H2-IA/IE (left) and HLA-DR (right) in models of IRF8 KO; WB of IRF8 in RIVA and SU-DHL2 KO models, and WB of MHCII in all IRF8 KO models in DLBCL. (B) FACS of CD74 in models of IRF8 KO. (C) FACS of H2-DM and HLA-DM in IRF8 KO models. (D) Left: FACS of CD74 and H2-DM in the IRF8 KO A20 lymphoma model “rescued” with IRF8 WT or missense or nonsense mutants (top and bottom). Right: FACS of CD74 and H2-DM in the IRF8 KO 2PK-3 lymphoma model “rescued” with IRF8 WT or missense and nonsense mutants (top and bottom). (E) Top: ChIP-qPCR of IRF8 binding to the indicated promot- ers – controls are IgG pull down, and a genomic region without a predicted IRF8 binding site (neg ctrl). Bottom: ChIP-qPCR of IRF8 WT, N87Y, or I424T binding to the Cd74, H2-Dm, Ciita, or H2-Aa promoters. (F) Top: WB of CD74 in 2PK-3 and A20 CD74-KO models. Bottom: IL-2 levels and % of CD4/CD25+ cells in IRF8/CD74 WT, IRF8 KO, or CD74 KOs models. (G) Left to right: A20, 2PK-3, and BCL1 models of IRF8 KO with CD74 ectopic expression (ee). WB of CD74-FLAG, IL-2 levels and % of CD4/CD25+ cells in IRF8/ CD74 WT, IRF8 KO, or IRF8KO + CD74. (H) Left: WB of CD74-FLAG in IRF8 WT, N87Y, and I424T A20 models. Right: IL-2 levels and % of CD4/CD25+ cells in IRF8 WT, N87Y, and I424T (−/+ CD74 ectopic expression) models. Data are means ± SD of three biological replicates. FACS displayed as relative mean fluorescence intensity (MFI). P values are from ANOVA, with Bonferroni or Fisher’s LSD posttest, or two-sided Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Article Snippet: Antibodies used for flow cytometry were the following: antihuman HLA- DR and anti- human HLA- DM, (catalog no. 361610 and catalog no. 358004, Biolegend), anti- human CD74 (catalog no. FAB35901N, R&D Systems); anti- mouse H2I- A/I- E, (catalog no. 10763), anti- mouse CD3 (catalog no. 100206), anti- mouse CD8a (catalog no. 100712), anti- mouse CD11b (catalog no. 101208), anti- mouse Nkp46 (catalog no. 137612), anti- mouse CD195 (CCR5) (catalog no. 107011), anti- mouse CD279 (PD- 1) (catalog no. 135224), anti- mouse CD185 (CXCR5) (catalog no. 145506), anti- mouse IL- 33Rα (ST2) (catalog no. 146607), anti- mouse CD193 (CCR3) (catalog no. 144527), anti- mouse CD4 (for Treg quantification, catalog no. 116023), anti- mouse FoxP3 (catalog no. 126403), anti- mouse CD25 (catalog no. 102037), anti- mouse CD127 (IL7Rα) (catalog no. 135011), anti- mouse Fc block CD16/32 (catalog no. 101302), all from Biolegend; anti- mouse H2- DM (catalog no. 624048), anti- mouse CD4 (catalog no. 563232), anti- mouse CD25 (catalog no. 553866), anti- mouse CD183 (CXCR3) (BDB755832), all from BD Biosciences; anti- mouse CD74 (FAB7478A, R&D Systems), anti- mouse Ly- 6G/Gr1 (catalog no. 17- 9668- 82, eBioscience). anti- mouse RORgt (catalog no. BDB562607, (BD Bioscience), antimouse GATA3 (catalog no. 50604769), anti–T- BET (catalog no. 50170980), anti- Human/mouse BCL6 (catalog no. 50604576), anti- mouse CD196 (catalog no. NC1898560); anti- mouse PD- 1 (catalog no. 135224), anti- mouse PD- L1 (catalog no. 17- 5982- 82), antimouse B220 (catalog no. 103208), anti- mouse CD69 (catalog no. 104514), all from Biolegend.

    Techniques: Control, ChIP-qPCR, Binding Assay, Expressing, Fluorescence

    Fig. 6. IRF8 effects on B cell lymphoma aggressiveness and immune microenvironment. (A) Growth curve of lymphomas expressing IRF8 WT, N87Y, Q392X, or I424T. (B) FACS-based quantification of CD3, CD4 and CD8 T cells in the TME of IRF8 WT or mutant lymphomas. (C) FACS-based quantification of Tregs and NK cells in the TME of IRF8 WT or mutant lymphomas. (D) IHC-based quantification of T cell infiltrate in B cell lymphomas expressing IRF8 WT, N87Y, or I424T. Representative staining (B220, pink; CD3, brown) is shown to the right, scale bar is displayed. (E) Growth curve of lymphomas expressing IRF8 WT, IRF8 N87Y or IRF8 I424T (−/+ CD74 expression). (F) FACS- based quantification of CD3, CD4 and CD8 in the TME of IRF8 WT or mutant lymphomas (−/+ CD74 expression). (G) FACS-based quantification of Tregs and NK cells in the TME of IRF8 WT or mutant lymphomas (−/+ CD74 expression). (H) TH1/TH2 ratio, TH1, TH2, and TFH cells in the TME of IRF8 WT or mutant lymphomas (−/+ CD74 expression). (I) TH1/TH2 ratio and TFH cells in the TME of IRF8 WT, missense (N87Y) or truncating (Q392X) mutant lymphomas. (J) Growth curve of lymphomas models expressing IRF8 WT or N87Y in mice treated with control antibody or anti–PD-L1 antibody; FACS-based quantification of CD4 and CD8 in IRF8 N87Y lymphomas treated with control or anti–PD-L1 antibody. For all panels, data are means ± SD of multiple independent cohorts (n indicated in the figure). P values are from one-way ANOVA with Fisher’s LSD posttest, Mann-Whitney test, or two-sided Student’s t test; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

    Journal: Science advances

    Article Title: IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes.

    doi: 10.1126/sciadv.adk2091

    Figure Lengend Snippet: Fig. 6. IRF8 effects on B cell lymphoma aggressiveness and immune microenvironment. (A) Growth curve of lymphomas expressing IRF8 WT, N87Y, Q392X, or I424T. (B) FACS-based quantification of CD3, CD4 and CD8 T cells in the TME of IRF8 WT or mutant lymphomas. (C) FACS-based quantification of Tregs and NK cells in the TME of IRF8 WT or mutant lymphomas. (D) IHC-based quantification of T cell infiltrate in B cell lymphomas expressing IRF8 WT, N87Y, or I424T. Representative staining (B220, pink; CD3, brown) is shown to the right, scale bar is displayed. (E) Growth curve of lymphomas expressing IRF8 WT, IRF8 N87Y or IRF8 I424T (−/+ CD74 expression). (F) FACS- based quantification of CD3, CD4 and CD8 in the TME of IRF8 WT or mutant lymphomas (−/+ CD74 expression). (G) FACS-based quantification of Tregs and NK cells in the TME of IRF8 WT or mutant lymphomas (−/+ CD74 expression). (H) TH1/TH2 ratio, TH1, TH2, and TFH cells in the TME of IRF8 WT or mutant lymphomas (−/+ CD74 expression). (I) TH1/TH2 ratio and TFH cells in the TME of IRF8 WT, missense (N87Y) or truncating (Q392X) mutant lymphomas. (J) Growth curve of lymphomas models expressing IRF8 WT or N87Y in mice treated with control antibody or anti–PD-L1 antibody; FACS-based quantification of CD4 and CD8 in IRF8 N87Y lymphomas treated with control or anti–PD-L1 antibody. For all panels, data are means ± SD of multiple independent cohorts (n indicated in the figure). P values are from one-way ANOVA with Fisher’s LSD posttest, Mann-Whitney test, or two-sided Student’s t test; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

    Article Snippet: Antibodies used for flow cytometry were the following: antihuman HLA- DR and anti- human HLA- DM, (catalog no. 361610 and catalog no. 358004, Biolegend), anti- human CD74 (catalog no. FAB35901N, R&D Systems); anti- mouse H2I- A/I- E, (catalog no. 10763), anti- mouse CD3 (catalog no. 100206), anti- mouse CD8a (catalog no. 100712), anti- mouse CD11b (catalog no. 101208), anti- mouse Nkp46 (catalog no. 137612), anti- mouse CD195 (CCR5) (catalog no. 107011), anti- mouse CD279 (PD- 1) (catalog no. 135224), anti- mouse CD185 (CXCR5) (catalog no. 145506), anti- mouse IL- 33Rα (ST2) (catalog no. 146607), anti- mouse CD193 (CCR3) (catalog no. 144527), anti- mouse CD4 (for Treg quantification, catalog no. 116023), anti- mouse FoxP3 (catalog no. 126403), anti- mouse CD25 (catalog no. 102037), anti- mouse CD127 (IL7Rα) (catalog no. 135011), anti- mouse Fc block CD16/32 (catalog no. 101302), all from Biolegend; anti- mouse H2- DM (catalog no. 624048), anti- mouse CD4 (catalog no. 563232), anti- mouse CD25 (catalog no. 553866), anti- mouse CD183 (CXCR3) (BDB755832), all from BD Biosciences; anti- mouse CD74 (FAB7478A, R&D Systems), anti- mouse Ly- 6G/Gr1 (catalog no. 17- 9668- 82, eBioscience). anti- mouse RORgt (catalog no. BDB562607, (BD Bioscience), antimouse GATA3 (catalog no. 50604769), anti–T- BET (catalog no. 50170980), anti- Human/mouse BCL6 (catalog no. 50604576), anti- mouse CD196 (catalog no. NC1898560); anti- mouse PD- 1 (catalog no. 135224), anti- mouse PD- L1 (catalog no. 17- 5982- 82), antimouse B220 (catalog no. 103208), anti- mouse CD69 (catalog no. 104514), all from Biolegend.

    Techniques: Expressing, Mutagenesis, Staining, Control, MANN-WHITNEY

    Figure 1: SP7219 and STRO-001 showed similar high affinity binding to human and cynomolgus monkey CD74, no binding to mouse CD74. Anti-GFP antibody SP7824 was used as negative control in the cell binding experiments. (A) SP7219 and STRO-001 showed similar high affinity cell binding on CHO cells over-expressing human and cynomolgus monkey CD74. (B) SP7219 and STRO-001 showed no binding to mouse B cell line A20. The mouse CD74 expression on A20 was confirmed by a commercial anti- mouse-CD74 antibody from R&D Systems.

    Journal: Oncotarget

    Article Title: Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.

    doi: 10.18632/oncotarget.28341

    Figure Lengend Snippet: Figure 1: SP7219 and STRO-001 showed similar high affinity binding to human and cynomolgus monkey CD74, no binding to mouse CD74. Anti-GFP antibody SP7824 was used as negative control in the cell binding experiments. (A) SP7219 and STRO-001 showed similar high affinity cell binding on CHO cells over-expressing human and cynomolgus monkey CD74. (B) SP7219 and STRO-001 showed no binding to mouse B cell line A20. The mouse CD74 expression on A20 was confirmed by a commercial anti- mouse-CD74 antibody from R&D Systems.

    Article Snippet: For the anti-mouse CD74 antibody conjugated to APC from R&D system (Cat. No. FAB7478A) which has no concentration information available, the antibody was mixed with cells at 1:1 volume ratio and then started 1:4 serial dilution.

    Techniques: Binding Assay, Negative Control, Expressing

    Figure 3: STRO-001 showed potent cell killing activity on proliferating primary human B cells. (A) In vitro expanded primary B cells showed increased CD86, HLA-DR and CD74 expression compared to naïve B cells. (B) In vitro expanded B cell showed improved proliferation activity compared to naïve B cells. Cell proliferation was analyzed by flow cytometry using propidium iodide exclusion. (C) STRO-001 showed more potent cell killing of proliferating B cells (EC50 = 0.49 nM) than naïve B cells (EC50 = 11 nM).

    Journal: Oncotarget

    Article Title: Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.

    doi: 10.18632/oncotarget.28341

    Figure Lengend Snippet: Figure 3: STRO-001 showed potent cell killing activity on proliferating primary human B cells. (A) In vitro expanded primary B cells showed increased CD86, HLA-DR and CD74 expression compared to naïve B cells. (B) In vitro expanded B cell showed improved proliferation activity compared to naïve B cells. Cell proliferation was analyzed by flow cytometry using propidium iodide exclusion. (C) STRO-001 showed more potent cell killing of proliferating B cells (EC50 = 0.49 nM) than naïve B cells (EC50 = 11 nM).

    Article Snippet: For the anti-mouse CD74 antibody conjugated to APC from R&D system (Cat. No. FAB7478A) which has no concentration information available, the antibody was mixed with cells at 1:1 volume ratio and then started 1:4 serial dilution.

    Techniques: Activity Assay, In Vitro, Expressing, Flow Cytometry